Allos
Allos AI is an Oxford University spinout selling a causal AI platform to pharmaceutical sponsors for formulation development, scale-up, tech transfer, and clinical trial optimization in specialty generics.
- Company typePrivate
- Founded2024
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Allos does
Allos AI is an Oxford University spinout that has built a causal AI platform targeted at pharmaceutical R&D, specifically formulation development for complex generics and small-molecule medicines for chronic conditions. The company's core technology combines causal inference with simulation-led Design of Experiments (DoE) and a closed-loop learning system to model cause-and-effect relationships between process interventions and outcomes before physical experiments are run. The platform is modularized into four product areas — Formulation Development, Scale-Up, Tech Transfer & QA, and Clinical Trials — each addressing a distinct phase of the molecule-to-validated-process workflow.
The product ingests structured experimental, process, and real-world data to perform phase-space mapping, identify robust operating windows, quantify sensitivities, and stratify patients. Disclosed validated outcomes include a 30% reduction in non-response rates to biologic therapies, 50% lower inter-patient variability, and 70% fewer scale-up and tech-transfer failures. The company positions its offering as the industry's first "glass-box" causal AI platform, contrasting its explainability with conventional black-box predictive models used in pharma R&D.
Commercially, Allos operates an enterprise direct-sales motion aimed at pharmaceutical sponsors, supported by a quote-based engagement model with no publicly disclosed pricing. Revenue mechanics span subscription/recurring AI platform services alongside professional services for formulation development. The company is headquartered in Oxford, United Kingdom, employs between 11 and 50 people, and was recently capitalized with a $5 million seed round led by Oxford Science Enterprises, with participation from Habico Invest (the family office of Danish pharma group Orifarm) and Berkeley SkyDeck. Note: a firmographic short description characterizes Allos as serving autoimmune prognosis/monitoring/treatment; the overwhelming majority of source material instead describes pharmaceutical formulation and R&D, which is the positioning used here.
Allos firmographics
Firmographics- Name
- Allos
- Legal name
- Allos AI
- Website
- https://allos.ai
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Allos AI is an Oxford University spinout selling a causal AI platform to pharmaceutical sponsors for formulation development, scale-up, tech transfer, and clinical trial optimization in specialty generics.
- Ownership category
- akta.pro rank
Allos industry classification
Industry- Product category
- Pharmaceutical R&D AI Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)
- SIC
- Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731), Services-Computer Programming Services (7371)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where Allos is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Allos business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- AI Platform Services: Providing causal AI platform services for formulation development, scale-up, tech transfer, QA, and clinical trials to pharmaceutical sponsors.
- Formulation Development Services: AI-powered formulation development services including phase-space mapping and simulation-led DoE for pharmaceutical companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Allos product offering
Product offeringCore offering
Allos develops and sells a Causal AI platform for pharmaceutical development that simulates how interventions affect outcomes, defining robust operating windows before experiments run. The platform combines integrated modules for formulation development, scale-up, tech transfer/QA, and clinical trials, learning from every run and deviation to serve as a single source of truth with traceable drivers. The company sells both the AI platform (subscription-based) and formulation development services to pharmaceutical sponsors.
Product overview
Allos offers a unified AI platform (Allos AI Platform) for pharmaceutical development that combines five integrated modules: Formulation Development, Scale-Up, Tech Transfer & QA, and Clinical Trials. The platform uses causal AI to simulate how interventions affect outcomes, enabling pharmaceutical companies to define robust operating windows before experiments run. The system delivers quantified improvements including 50% lower inter-patient variability and 70% fewer scale-up and tech transfer failures.
Differentiator
Problem solved
Functional benefit
Products and services
- Allos AI Platform A causal AI platform that simulates how interventions affect outcomes in pharmaceutical development, defining robust operating windows before experiments run. The closed-loop system learns from every run and deviation, serving as a single source of truth with traceable drivers, documented assumptions, and controlled version history. Targeted at pharmaceutical sponsors developing specialty generics and complex small-molecule drugs for chronic conditions.
- Formulation Development Services
Quantifiable outcome
- 30% reduction in non-response rates to biologic therapies
- +2 more outcomes
Companies that use Allos
Customer profileSegments1 record
Ideal customer profiles1 record
Allos technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Allos partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights5 records
Allos competitors and assessment
Company assessmentDirect peers
- Schrödinger: Physics-based and AI-driven computational platform for drug discovery and materials science. Direct competitor in applying advanced modeling to pharmaceutical R&D, though broader in scope across discovery rather than formulation.
- XtalPi: AI and robotics platform combining computation with experimental automation for drug discovery and crystalline formulation. Closely aligned to Allos on AI-led formulation and process optimization for pharma.
- Simulations Plus: Provides modeling and simulation software for pharmaceutical formulation, PK/PD, and regulatory submissions. Highly comparable given the overlap on AI-driven formulation and scale-up workflows.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning. Comparable as a peer using AI/ML to compress pharmaceutical R&D cycles, though focused on novel therapeutics rather than formulation.
- Insitro: Machine learning-driven drug discovery platform combining computational biology with high-throughput experimental data. Comparable in applying AI/ML to improve pharma R&D success rates.
- Atomwise: AI platform for small-molecule drug discovery using structure-based deep learning. Comparable in deploying AI for pharmaceutical development, particularly for small-molecule medicines targeted by Allos.
Broad incumbents
- Certara: Established provider of model-informed drug development software and services spanning discovery, formulation, and regulatory. Overlaps with Allos on tech-transfer and CMC simulation but at significantly larger scale.
- Benchling: Cloud platform for life sciences R&D covering experiment tracking, molecular biology, and process development. Comparable as an informatics backbone for pharma R&D, though a broader platform than Allos's causal AI focus.
- Dotmatics: Scientific informatics platform for R&D data, workflows, and analytics across pharma and biotech. Comparable as an enabling informatics layer for pharmaceutical development teams.
- Genedata: Enterprise software for biopharma R&D workflows across discovery, development, and manufacturing. Comparable as an established informatics vendor competing for similar IT budgets in pharma R&D organizations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Allos social profiles
Digital presenceAllos financial estimates
Financial estimateRevenue estimate
Valuation estimate
Allos leadership team
Management profileNumber of profiles
Profiles1 record
Allos funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Allos M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Allos
What does Allos do?
Allos develops and sells a Causal AI platform for pharmaceutical development that simulates how interventions affect outcomes, defining robust operating windows before experiments run. The platform combines integrated modules for formulation development, scale-up, tech transfer/QA, and clinical trials, learning from every run and deviation to serve as a single source of truth with traceable drivers. The company sells both the AI platform (subscription-based) and formulation development services to pharmaceutical sponsors.
Is Allos a public or private company?
Allos is a private company. It is classified as venture growth investor backed and is currently operating.
When was Allos founded?
Allos was founded in 2024. It employs 11 to 50 people.
Where is Allos based?
Allos is headquartered in London, United Kingdom, in the Europe region.
How does Allos make money?
Two revenue lines are on record. AI Platform Services are the primary driver. The others are formulation Development Services.
Who are Allos's main competitors?
Direct peers on record are Schrödinger, XtalPi, Simulations Plus, Recursion Pharmaceuticals, Insitro and Atomwise. Broad incumbents are Certara, Benchling, Dotmatics and Genedata.
Does Allos have an API?
No public API is recorded for Allos.
What industry is Allos in?
Allos's product category is Pharmaceutical R&D AI Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 541714 and its SIC code is 7372.